A BILL 
To direct the Commissioner of Food and Drugs to amend 
certain regulations to increase clinical trial diversity, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Diverse and Equitable 
4
Participation in Clinical Trials Act’’ or the ‘‘DEPICT 
5
Act’’. 
6
18:00 Feb 09, 2022
H6584
2 
•HR 6584 IH
SEC. 2. PREMARKET REPORTING OF DIVERSITY PLANS FOR 
1
CLINICAL TRIALS AND STUDIES. 
2
(a) DRUGS.—The Commissioner of Food and Drugs 
3
shall issue regulations revising part 312 of title 21, Code 
4
of Federal Regulations, to require sponsors of applications 
5
for an exemption for investigational use of a drug to in-
6
clude— 
7
(1) in any such application— 
8
(A) the estimated prevalence in the United 
9
States of the disease or condition for which the 
10
drug 
is 
being 
developed 
or 
investigated, 
11
disaggregated by demographic subgroup, where 
12
such data is available, including age group, sex, 
13
race, and ethnicity; 
14
(B) the sponsor’s targets for enrollment in 
15
the 
clinical 
trial 
or 
trials 
involved, 
16
disaggregated by age group, sex, race, and eth-
17
nicity; 
18
(C) the rationale for the sponsor’s enroll-
19
ment targets referred to in subparagraph (B), 
20
which may include— 
21
(i) the estimated prevalence referred 
22
to in subparagraph (A); 
23
(ii) what is known about the disease 
24
or condition for which the drug is being 
25
developed or investigated; 
26
18:00 Feb 09, 2022
H6584
3 
•HR 6584 IH
(iii) any relevant pharmacokinetic or 
1
pharmacogenomic data; 
2
(iv) what is known about the patient 
3
population, including co-morbidities and 
4
potential barriers to enrolling diverse par-
5
ticipants, such as patient population size 
6
and geographic location; and 
7
(v) any other data or information the 
8
sponsors deems relevant to selecting appro-
9
priate enrollment targets, disaggregated by 
10
demographic subgroup; and 
11
(D) a diversity action plan for how the 
12
sponsor will meet such targets, including demo-
13
graphic-specific outreach and enrollment strate-
14
gies, study-site selection, clinical trial inclusion 
15
and exclusion practices, and any diversity train-
16
ing for trial personnel; and 
17
(2) in an annual report described in section 
18
312.33 of title 21, Code of Federal Regulations— 
19
(A) the sponsor’s progress in meeting the 
20
targets referred to in paragraph (1)(B); and 
21
(B) if the sponsor does not expect to meet 
22
those targets referred to in paragraph (1)(B)— 
23
18:00 Feb 09, 2022
H6584
4 
•HR 6584 IH
(i) any updates needed to be made to 
1
the diversity action plan referred to in 
2
paragraph (1)(D) to meet such targets; or 
3
(ii) the sponsor’s justification for why 
4
the sponsor does not expect to meet such 
5
targets, including— 
6
(I) any factors outside of the 
7
sponsor’s control, including a lack of 
8
retention of participants; 
9
(II) any differences in the enroll-
10
ment targets, disaggregated by demo-
11
graphic subgroup, and actual enroll-
12
ment that the sponsor determines are 
13
insignificant in nature; 
14
(III) potential for selection bias; 
15
and 
16
(IV) information not available to 
17
the sponsor at the time such targets 
18
were chosen, but that impacted enroll-
19
ment of diverse participants. 
20
(b) DEVICES.—The Commissioner of Food and 
21
Drugs shall issue regulations revising part 812 of title 21, 
22
Code of Federal Regulations, to require sponsors of appli-
23
cations for an exemption for investigational use of a device 
24
to include— 
25
18:00 Feb 09, 2022
H6584
5 
•HR 6584 IH
(1) in any such application— 
1
(A) a description of the patient population 
2
in the United States expected to use the device, 
3
disaggregated by demographic subgroup, where 
4
such data is available, including age group, sex, 
5
race, and ethnicity; 
6
(B) the sponsor’s targets for enrollment in 
7
the 
clinical 
trial 
or 
trials 
involved, 
8
disaggregated by age group, sex, race, and eth-
9
nicity; 
10
(C) the rationale for the sponsor’s enroll-
11
ment targets referred to in subparagraph (B), 
12
which may include— 
13
(i) the estimated prevalence referred 
14
to in subparagraph (A); 
15
(ii) what is known about the disease 
16
or condition for which the drug is being 
17
developed or investigated; 
18
(iii) any relevant pharmacokinetic or 
19
pharmacogenomic data; 
20
(iv) what is known about the patient 
21
population, including co-morbidities and 
22
potential barriers to enrolling diverse par-
23
ticipants, such as patient population size 
24
and geographic location; and 
25
18:00 Feb 09, 2022
H6584
6 
•HR 6584 IH
(v) any other data or information the 
1
sponsors deems relevant to selecting appro-
2
priate enrollment targets, disaggregated by 
3
demographic subgroup; and 
4
(D) a diversity action plan for how the 
5
sponsor will meet such targets, including demo-
6
graphic-specific outreach and enrollment strate-
7
gies, study-site selection, clinical trial inclusion 
8
and exclusion practices, and any diversity train-
9
ing for trial personnel; and 
10
(2) in an annual report described in section 
11
812.150 of title 21, Code of Federal Regulations— 
12
(A) the sponsor’s progress in meeting 
13
those targets referred to in paragraph (1)(B); 
14
and 
15
(B) if the sponsor does not expect to meet 
16
those targets referred to in paragraph (1)(B)— 
17
(i) any updates needed to be made to 
18
the diversity action plan referred to in 
19
paragraph (1)(D) to meet such targets; or 
20
(ii) the sponsor’s justification for why 
21
the sponsor does not expect to meet such 
22
targets, including— 
23
18:00 Feb 09, 2022
H6584
7 
•HR 6584 IH
(I) any factors outside of the 
1
sponsor’s control, including a lack of 
2
retention of participants; 
3
(II) any differences in the enroll-
4
ment targets, disaggregated by demo-
5
graphic subgroup, and actual enroll-
6
ment that the sponsor determines are 
7
insignificant in nature; 
8
(III) potential for selection bias; 
9
and 
10
(IV) information not available to 
11
the sponsor at the time such targets 
12
were chosen, but that impacted enroll-
13
ment of diverse participants. 
14
(c) ADDITIONAL CLINICAL TRIAL DATA.—The Com-
15
missioner of Food and Drugs shall issue regulations revis-
16
ing sections 807.92 and 814.20 of title 21, Code of Fed-
17
eral Regulations, to require that applications for devices 
18
approved under section 515 of the Federal Food, Drug, 
19
and Cosmetic Act (21 U.S.C. 360e) and devices cleared 
20
under section 510(k) of such Act (21 U.S.C. 360(k)) 
21
whose submission includes clinical data— 
22
(1) a description of the patient population in 
23
the United States expected to use the device, 
24
disaggregated by demographic subgroup, where such 
25
18:00 Feb 09, 2022
H6584
8 
•HR 6584 IH
data is available, including age group, sex, race, and 
1
ethnicity; and 
2
(2) in summarizing the clinical investigations 
3
involving human subjects in such applications, a de-
4
scription of study subjects by demographic sub-
5
group, including age group, sex, race, and ethnicity. 
6
(d) DEADLINE FOR PROMULGATION.—The Commis-
7
sioner of Food and Drugs shall issue— 
8
(1) any proposed rules required under this sec-
9
tion not later than 2 years after the date of the en-
10
actment of this Act; and 
11
(2) any final rules required under this section 
12
not later than 3 years after the date of the enact-
13
ment of this Act. 
14
SEC. 3. FDA AUTHORITY TO MANDATE POSTAPPROVAL 
15
STUDIES OR POSTMARKET SURVEILLANCE 
16
DUE TO INSUFFICIENT DEMOGRAPHIC SUB-
17
GROUP DATA. 
18
(a) DRUGS.— 
19
(1) IN GENERAL.—Section 505(o)(3)(B) of the 
20
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
21
355(o)(3)(B)) is amended by adding at the end the 
22
following: 
23
18:00 Feb 09, 2022
H6584
9 
•HR 6584 IH
‘‘(iv) To provide safety and effective-
1
ness data for the drug involved for a demo-
2
graphic subgroup or subgroups, if— 
3
‘‘(I) the clinical trials conducted 
4
in support of the approval of the drug 
5
did not meet the applicable targets of 
6
enrollment, as described in section 2 
7
of the DEPICT Act; and 
8
‘‘(II) in the judgment of the Sec-
9
retary, additional data could inform 
10
drug labeling.’’. 
11
(2) WAIVER.—Section 505(o)(3)(D) of the Fed-
12
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
13
355(o)(3)(D)) is amended by adding at the end the 
14
following: 
15
‘‘(iii) CLINICAL TRIAL DIVERSITY EN-
16
ROLLMENT.—The Secretary may not re-
17
quire postapproval studies or postapproval 
18
clinical trials for the purpose specified 
19
under subparagraph (B)(iv) if the sponsor 
20
provides to the Secretary a sufficient jus-
21
tification for not meeting the enrollment 
22
targets referred to in such subparagraph, 
23
which may include— 
24
18:00 Feb 09, 2022
H6584
10 
•HR 6584 IH
‘‘(I) factors outside of the spon-
1
sor’s control, such as a lack of reten-
2
tion of participants; 
3
‘‘(II) differences in the enroll-
4
ment targets, disaggregated by demo-
5
graphic subgroup, and actual enroll-
6
ment that are determined by the Sec-
7
retary to be insignificant in nature; 
8
‘‘(III) information not available 
9
to the sponsor at the time such enroll-
10
ment targets were chosen, but that 
11
impacted enrollment of diverse partici-
12
pants; 
13
‘‘(IV) potential for selection bias; 
14
and 
15
‘‘(V) any other reason that the 
16
Secretary determines is sufficient jus-
17
tification.’’. 
18
(3) USE OF REAL WORLD EVIDENCE.—Section 
19
505(o)(3) of the Federal Food, Drug, and Cosmetic 
20
Act (21 U.S.C. 355(o)(3)) is amended by adding at 
21
the end the following: 
22
‘‘(G) USE OF REAL WORLD EVIDENCE.— 
23
Real world evidence (as defined in section 
24
18:00 Feb 09, 2022
H6584
11 
•HR 6584 IH
505F(b)) may be used to support or satisfy the 
1
requirements under this paragraph.’’. 
2
(b) DEVICES.—Section 522(a)(1) of the Federal 
3
Food, Drug, and Cosmetic Act (21 U.S.C. 360l(a)(1)(A)) 
4
is amended— 
5
(1) in subparagraph (A)— 
6
(A) in clause (ii), by striking ‘‘or’’ at the 
7
end; 
8
(B) in clause (iii)(II), by striking ‘‘facil-
9
ity.’’ and inserting ‘‘facility; or’’; and 
10
(C) by adding at the end the following: 
11
‘‘(iv) with respect to which— 
12
‘‘(I) clinical studies submitted to 
13
support that approval or clearance did 
14
not meet the applicable targets of en-
15
rollment, as described in section 2 of 
16
the DEPICT Act; and 
17
‘‘(II) with respect to which a jus-
18
tification described in subparagraph 
19
(D) is not provided.’’; and 
20
(2) by adding at the end the following: 
21
‘‘(C) USE OF REAL WORLD EVIDENCE.— 
22
Real world evidence (as defined in section 
23
505F(b)) may be used to support or satisfy the 
24
requirements under this paragraph. 
25
18:00 Feb 09, 2022
H6584
12 
•HR 6584 IH
‘‘(D) CLINICAL TRIAL DIVERSITY ENROLL-
1
MENT.—The Secretary may not require a man-
2
ufacturer to conduct postmarket surveillance 
3
under subparagraph (A) with respect to a de-
4
vice for the purpose specified in clause (iv) of 
5
such subparagraph if the manufacturer provides 
6
to the Secretary a sufficient justification for not 
7
meeting the enrollment targets referred to in 
8
such subparagraph, which may include— 
9
‘‘(i) factors outside of the manufac-
10
turer’s control, such as a lack of retention 
11
of participants; 
12
‘‘(ii) differences in the enrollment tar-
13
gets, disaggregated by demographic sub-
14
group, and actual enrollment that are de-
15
termined by the Secretary to be insignifi-
16
cant in nature; 
17
‘‘(iii) information not available to the 
18
manufacturer at the time such enrollment 
19
targets were chosen, but that impacted en-
20
rollment of diverse participants; 
21
‘‘(iv) potential for selection bias; and 
22
‘‘(v) any other reason that the Sec-
23
retary determines is sufficient justifica-
24
tion.’’. 
25
18:00 Feb 09, 2022
H6584
13 
•HR 6584 IH
(c) REPORTS FOR CERTAIN DEVICES.—The Commis-
1
sioner of Food and Drugs shall issue regulations revising 
2
section 814.84 of title 21, Code of Federal Regulations, 
3
to require holders of an application approved under section 
4
515 of the Federal Food, Drug, and Cosmetic Act (21 
5
U.S.C. 360e) to include in the reports submitted under 
6
such section 814.84, to the extent possible, any data not 
7
previously submitted under such section 814.84 that may 
8
inform the safety and effectiveness of the device involved 
9
in underrepresented demographic subgroups. 
10
(d) REGISTRY AND RESULTS DATA BANK INCLU-
11
SION.—Section 402(j)(1)(A) of the Public Health Service 
12
Act (282(j)(1)(A)) is amended— 
13
(1) in clause (ii)— 
14
(A) in subclause (I), by striking ‘‘and’’ at 
15
the end; 
16
(B) in subclause (II), by striking the pe-
17
riod at the end and inserting ‘‘; and’’; and 
18
(C) by adding at the end the following: 
19
‘‘(III) postmarket surveillance for 
20
any device as required under clause 
21
(iv) of section 522(a)(1)(A) of the 
22
Federal Food, Drug, and Cosmetic 
23
Act.’’; and 
24
18:00 Feb 09, 2022
H6584
14 
•HR 6584 IH
(2) in clause (iii)(I), by striking the period at 
1
the end and inserting the following: ‘‘, including any 
2
postapproval study or postapproval clinical trial for 
3
a drug as required under section 505(o)(3)(B)(iv) of 
4
the Federal Food, Drug, and Cosmetic Act.’’. 
5
(e) PUBLIC MEETING.— 
6
(1) IN
GENERAL.—Not later than 270 days 
7
after the date of enactment of this Act, the Sec-
8
retary, acting through the Commissioner of Food 
9
and Drugs, and in consultation with drug sponsors, 
10
medical device manufacturers, patients, and other 
11
stakeholders, shall convene a public meeting to con-
12
sider the ways by which— 
13
(A) drug sponsors and medical device man-
14
ufacturers may disseminate information to the 
15
public on clinical trial enrollment demographic 
16
data in a timely and accessible manner; 
17
(B) drug and device sponsors, in consulta-
18
tion with the Commissioner of Food and Drugs, 
19
may publicly disseminate information on sub-
20
group analyses conducted by the sponsors in 
21
cases where— 
22
(i) such data is not sufficient for the 
23
purpose of updating drug and device la-
24
bels; or 
25
18:00 Feb 09, 2022
H6584
15 
•HR 6584 IH
(ii) such analyses do not show signifi-
1
cant differences between demographic sub-
2
groups; and 
3
(C) drug and device sponsors, in consulta-
4
tion with the Commissioner of Food and Drugs, 
5
may collect and publicly disseminate real world 
6
evidence that may provide information on the 
7
safety and effectiveness of drugs or devices for 
8
a demographic subgroup or subgroups. 
9
(2) REPORT.—Not later than 180 days after 
10
the date on which the public meeting is convened 
11
under paragraph (1), the Secretary shall make avail-
12
able on the website of the Food and Drug Adminis-
13
tration a report on the topics discussed at such 
14
meeting. The report shall include a summary of, and 
15
response to, recommendations raised in such meet-
16
ing. 
17
SEC. 4. ANNUAL REPORT ON PROGRESS TO INCREASE DI-
18
VERSITY IN CLINICAL TRIALS AND STUDIES. 
19
(a) IN GENERAL.—Beginning not later than 2 years 
20
after the date of the enactment of this Act, and each year 
21
thereafter, the Secretary of Health and Human Services, 
22
acting through the Commissioner of Food and Drugs, 
23
shall submit to Congress, and publish on the public 
24
website of the Food and Drug Administration, a report 
25
18:00 Feb 09, 2022
H6584
16 
•HR 6584 IH
that addresses progress on increasing diversity in clinical 
1
trial and study enrollment. 
2
(b) CONTENTS OF REPORT.—The report submitted 
3
under subsection (a) shall include, with respect to applica-
4
tions for drugs or devices approved or cleared under sec-
5
tion 505, 510(k), or 515 of the Federal Food, Drug, and 
6
Cosmetic Act (21 U.S.C. 355, 360(k), or 360e) or licensed 
7
under section 351 of the Public Health Service Act (42 
8
U.S.C. 262) during the calendar year that immediately 
9
precedes the year in which the report is submitted— 
10
(1) an analysis of the extent to which clinical 
11
trials conducted with respect to such applications 
12
have met the demographic subgroup enrollment tar-
13
gets for clinical trials and studies required by the 
14
regulations amended pursuant to section 2 and the 
15
amendments made by section 3; 
16
(2) the frequency with which enrollment targets 
17
by demographic subgroup set for a clinical trial con-
18
ducted under an exemption for investigational use of 
19
a drug under section 505(i) of the Federal Food, 
20
Drug, and Cosmetic Act (21 U.S.C. 355(i)) or sec-
21
tion 351 of the Public Health Service Act (42 
22
U.S.C. 262) or an exemption for investigational use 
23
of a device under section 520(g) of the Federal 
24
Food, Drug, and Cosmetic Act (21 U.S.C. 360j(g)) 
25
18:00 Feb 09, 2022
H6584
17 
•HR 6584 IH
do not adequately reflect the incidence in the United 
1
States population of the disease or condition being 
2
studied in the clinical trial and a summary of the ra-
3
tionales provided for enrollment targets by demo-
4
graphic subgroup in such cases; 
5
(3) a summary of the justifications sponsors 
6
provided in the cases where sponsors did not meet 
7
the enrollment targets specified pursuant to section 
8
2, disaggregated by demographic subgroup; and 
9
(4) the Secretary’s recommendations, as appro-
10
priate, for strategies presented in such diversity 
11
plans to attain enrollment targets that should be 
12
adopted by sponsors as best practices. 
13
(c) POSTMARKET STUDIES.—Beginning 3 years after 
14
the first instance in which the Secretary requires the spon-
15
sor of an application for a drug or device approved or 
16
cleared under section 505, 510(k), or 515 of the Federal 
17
Food, Drug, and Cosmetic Act (21 U.S.C. 355, 360(k), 
18
or 360e) or licensed under section 351 of the Public 
19
Health Service Act (42 U.S.C. 262) to conduct postmarket 
20
studies or postmarket surveillance under clause (iv) of sec-
21
tion 505(o)(3)(B) and clause (iv) of section 522(a)(1)(A) 
22
of the Federal Food, Drug, and Cosmetic Act (as added 
23
by subsections (a) and (b) of section 3), and each year 
24
18:00 Feb 09, 2022
H6584
18 
•HR 6584 IH
thereafter, the report submitted under subsection (a) shall 
1
also include— 
2
(1) the number of such applications that were 
3
required to initiate postmarket studies or surveil-
4
lance in the previous calendar year under clause (iv) 
5
of section 505(o)(3)(B) and clause (iv) of section 
6
522(a)(1)(A) of the Federal Food, Drug, and Cos-
7
metic Act (as added by subsections (a) and (b) of 
8
section 3), the numbers of such applications that 
9
have, as of the end of the calendar year immediately 
10
preceding the year in which the report is submitted, 
11
in-progress postmarket requirements, and the num-
12
ber of such applications that have completed 
13
postmarket requirements for each year, beginning on 
14
the date of the enactment of this Act; 
15
(2) an analysis of the average amount of time 
16
for completion of such postmarket requirements, 
17
disaggregated by type of application and type of 
18
postmarket requirement; 
19
(3) an analysis of how the imposition of such 
20
postmarket requirements has impacted the avail-
21
ability of demographic subgroup-specific safety and 
22
efficacy data for drugs, biologics, and devices; and 
23
(4) the Secretary’s recommendations, as appro-
24
priate, for additional guidance or postmarket re-
25
18:00 Feb 09, 2022
H6584
19 
•HR 6584 IH
quirements to facilitate the collection and reporting 
1
of representative demographic subgroup data in sup-
2
port of applications for the approval or clearance of, 
3
or updates to the labeling of, drugs and devices 
4
under section 505, 510(k), or 515 of the Federal 
5
Food, Drug, and Cosmetic Act (21 U.S.C. 355, 
6
360(k), or 360e) or licensure of biological products 
7
under section 351 of the Public Health Service Act 
8
(42 U.S.C. 262). 
9
(d) CONFIDENTIALITY.—Nothing in this section shall 
10
be construed as authorizing the Secretary to disclose any 
11
information that is a trade secret or confidential informa-
12
tion subject to section 552(b)(4) of title 5, United States 
13
Code, or section 1905 of title 18, United States Code. 
14
SEC. 5. PUBLIC MEETING ON CLINICAL TRIAL FLEXIBILI-
15
TIES INITIATED IN RESPONSE TO COVID–19 
16
PANDEMIC. 
17
(a) IN GENERAL.—Not later than 180 days after the 
18
date on which the COVID–19 emergency period ends, the 
19
Secretary of Health and Human Services shall convene a 
20
public meeting to discuss the regulatory flexibilities adopt-
21
ed by the Food and Drug Administration during the 
22
COVID–19 emergency period to mitigate disruption of 
23
clinical studies and clinical trials, including flexibilities de-
24
tailed in the March 2020 guidance entitled ‘‘Conduct of 
25
18:00 Feb 09, 2022
H6584
20 
•HR 6584 IH
Clinical Trials of Medical Products During the COVID- 
1
19 Public Health Emergency, Guidance for Industry, In-
2
vestigators, and Institutional Review Boards’’, and any 
3
subsequent updates to such guidance. The Secretary shall 
4
invite to such meeting representatives from the pharma-
5
ceutical and medical device industries who sponsored clin-
6
ical trials and clinical studies during the COVID–19 emer-
7
gency period and organizations representing patients. 
8
(b) TOPICS.—Not later than 90 days after the date 
9
on which the public meeting under subsection (a) is con-
10
vened, the Secretary shall make available on the public 
11
website of the Food and Drug Administration a report on 
12
the topics discussed at such meeting. Such topics shall in-
13
clude discussion of— 
14
(1) the actions drug sponsors took to utilize 
15
such regulatory flexibilities and the frequency at 
16
which such flexibilities were employed; 
17
(2) the characteristics of the sponsors, trials, 
18
and patient populations impacted by such regulatory 
19
flexibilities; 
20
(3) a consideration of how regulatory flexibili-
21
ties to mitigate disruption of clinical trials during 
22
the COVID–19 emergency period, including decen-
23
tralized clinical trials, may have affected access to 
24
clinical studies and trials for certain patient popu-
25
18:00 Feb 09, 2022
H6584
21 
•HR 6584 IH
lations, especially unrepresented racial and ethnic 
1
minorities; and 
2
(4) recommendations for incorporating certain 
3
clinical trial disruption mitigation flexibilities into 
4
current or additional guidance to improve clinical 
5
trial access and enrollment of diverse patient popu-
6
lations. 
7
(c) COVID–19 EMERGENCY PERIOD DEFINED.—In 
8
this section, the term ‘‘COVID–19 emergency period’’ has 
9
the meaning given the term ‘‘emergency period’’ in section 
10
1135(g)(1)(B) of the Social Security Act (42 U.S.C. 
11
1320b–5(g)(1)(B)). 
12
SEC. 6. COMMUNITY ENGAGEMENT AND OUTREACH TO IM-
13
PROVE INCLUSION OF UNDERREPRESENTED 
14
MINORITIES IN CLINICAL TRIALS AND RE-
15
SEARCH. 
16
(a) IN GENERAL.—The Secretary of Health and 
17
Human Services, acting through the Director of the Na-
18
tional Institutes of Health, shall conduct, coordinate, and 
19
support activities for purposes of community engagement 
20
with, and outreach to, underserved communities to facili-
21
tate inclusion of underrepresented minorities in clinical re-
22
search and clinical trials. 
23
18:00 Feb 09, 2022
H6584
22 
•HR 6584 IH
(b) ACTIVITIES.—Activities conducted, coordinated, 
1
or supported under this section may be for any of the fol-
2
lowing purposes: 
3
(1) Developing and disseminating best practices 
4
for community engagement and outreach and for in-
5
clusive participation in clinical research and trials. 
6
(2) Creating and providing tools and edu-
7
cational resources— 
8
(A) to facilitate adoption of such best prac-
9
tices by researchers and clinical trial sponsors; 
10
and 
11
(B) to encourage awareness of, and partici-
12
pation in, clinical trials and research among 
13
underrepresented minorities. 
14
(3) Engaging community stakeholders in under-
15
represented racial and ethnic minority communities 
16
and fostering partnerships with community-based or-
17
ganizations serving underrepresented racial and eth-
18
nical minority populations to encourage participation 
19
in clinical trials and research. 
20
(4) Conducting and supporting community en-
21
gagement research. 
22
(c) SUPPLEMENT, NOT SUPPLANT.—Grants under 
23
this subsection shall be used to supplement and not sup-
24
plant existing initiatives and programs at the National In-
25
18:00 Feb 09, 2022
H6584
23 
•HR 6584 IH
stitutes of Health to improve diversity in clinical trials and 
1
research. 
2
SEC. 7. GRANTS TO INCREASE THE CAPACITY OF COMMU-
3
NITY HEALTH CENTERS TO PARTICIPATE IN 
4
CLINICAL TRIALS AND RESEARCH. 
5
(a) IN GENERAL.—The Secretary of Health and 
6
Human Services, acting through the Administrator of the 
7
Health Resources and Services Administration and in con-
8
sultation with the Director of the National Institutes of 
9
Health, shall award grants to, and enter into cooperative 
10
agreements with, qualified entities to increase capacity at 
11
such qualified entities to participate in clinical trials and 
12
research by— 
13
(1) enhancing and expanding infrastructure at 
14
community health centers to support participation in 
15
clinical trials and research, including information 
16
technology improvements and the hiring and train-
17
ing of healthcare personnel, such as patient naviga-
18
tors and culturally trained site personnel to conduct, 
19
or recruit for, clinical trials; 
20
(2) reimbursing administrative costs and pa-
21
tient care costs incurred by qualified entities in the 
22
course of clinical research and trials that are not 
23
otherwise reimbursable by existing payers; and 
24
18:00 Feb 09, 2022
H6584
24 
•HR 6584 IH
(3) implementing community education and 
1
outreach strategies. 
2
(b) QUALIFIED ENTITIES DEFINED.—In this section, 
3
the term ‘‘qualified entity’’ means— 
4
(1) rural health clinics, as defined in section 
5
1861(aa)(2) of the Social Security Act (42 U.S.C. 
6
1395x(aa)(2)); 
7
(2) federally-qualified health centers described 
8
in section 1861(aa)(4)(B) of the Social Security Act 
9
(42 U.S.C. 1395x(aa)(4)(B)); 
10
(3) facilities operated by the Indian Health 
11
Service, an Indian Tribe, Tribal Organization, or an 
12
Urban Indian organization, as those terms are de-
13
fined in section 4 of the Indian Health Care Im-
14
provement Act (25 U.S.C. 1603); and 
15
(4) entities eligible to receive funds under sec-
16
tion 330 of the Public Health Service Act (42 
17
U.S.C. 254b). 
18
SEC. 8. AUTHORIZATION OF APPROPRIATIONS. 
19
There is authorized to be appropriated to carry out 
20
this Act, $100,000,000 for the period of fiscal years 2022 
21
through 2025. 
22
Æ 
18:00 Feb 09, 2022
H6584
